Health stocks spent another day dipping into the red as business and clinical news were not enough to overcome the broader market sentiment.

Vertex Pharmaceuticals

(VRTX) - Get Vertex Pharmaceuticals Incorporated Report

said it sold the rights to future royalties in HIV drugs Lexiva and Agenerase for a one-time cash payment of $160 million. Both products are marketed by


(GSK) - Get GlaxoSmithKline plc Sponsored ADR Report

under a 1993 agreement. Agenerase has been largely replaced by Lexiva, which is marketed as Telzir in Europe. Vertex shares added 98 cents, or 3.4%, to $29.53, while Glaxo zigzagged to settle relatively flat at $43.71.

Gains in Vertex and

OSI Pharmaceuticals

( OSIP), which was up 6% Tuesday, weren't enough to pull up the Amex Biotechnology index, which finished flat at 758.24. Components


( DNA) and


( CEPH) each lost more than a dollar, falling 1.7% and 1.8%, respectively.

VNUS Medical Technologies

( VNUS) said Tuesday that it entered into an agreement with


(ANGO) - Get AngioDynamics, Inc. Report

TheStreet Recommends


Vascular Solutions


to settle patent litigation that began in 2005. Venus is granting the companies a non-exclusive, non-sublicensable patent covering certain endovenous laser products.

AngioDynamics and Vascular Soutions will make upfront payments of $6.8 million and $3.1 million, respectively, for past litigation, and will pay a per unit royalty payments for endovenous laser products sold of shipped in the U.S. until 2017.

Venus shares rose 16.5% to $20.52, AngioDynamics finished flat on light volume, and Vascular Solutions added 74 cents, or 11.7%, to $7.06.

In ratings, Stanford Group initiated research on


with a buy rating and $13 price target. Shares ended up 23 cents, or 2.4%, at $9.97 on Tuesday.

Elsewhere, on the clinical side,

Auxilium Pharmaceuticals


shares added $1.14, or 3.6%, to $32.67 Tuesday after announcing positive top-line results from the CORD I and CORD II phase III clinical trials and also the results from a pharmacokinetic study on Xiaflex, a potential treatment for a condition that affects the connective tissue beneath the skin in the palm.


Avant Immunotherapies

( AVAN) gave back $1.08, or 6%, to $16.90 on Tuesday after surging 28% to a new 52-week high on Monday. The company and partner


(PFE) - Get Pfizer Inc. Report

gave updated data on two small studies on CDX-110, an experimental treatment for aggressive brain cancer, earlier in the week at the American Society of Clinical Oncology annual meeting, sending shares on Monday's joy ride.